$0.66
▼ -1.1% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Outlook Therapeutics Appoints Kevin Lundquist as CFO
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Overview
52-week range
$0.16
$2.54
21% of range
Avg surprise (last 3)
-3.6%
Avg reaction (last 2)
-3.1%
0% positive
Latest IV / EM
387%
EM ±60.5% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.15 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.16 | $-0.12 | -33.3% | +60.0% | -2.1% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.38 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.44 | $-0.42 | -4.8% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.40 | $-0.55 | +27.3% | — | -4.0% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $0.72 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.89 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-8.01 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.61 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.52 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $2M | — | — | — |
| Cost of revenue | $16,965 | $149,327 | $29,626 | — | $439,815 | — | — | — |
| Gross profit | $-8,265 | $-21,888 | $-1M | — | $1M | — | — | — |
| Operating income | $-11M | $-14M | $-13M | — | $-16M | $-12M | $-22M | — |
| Net income | $-20M | $-4M | $-23M | — | $-20M | $-46M | $17M | — |
| EPS (diluted) | $-0.15 | $-0.05 | $-0.38 | — | $-0.55 | $-1.50 | $0.72 | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $8M | $9M | $8M | $9M | $8M | $6M | $15M |
| Inventory | $5M | $3M | $3M | $3M | $4M | $4M | $3M | — |
| Total current assets | $23M | $21M | $17M | $17M | $21M | $18M | $16M | $27M |
| Total assets | $26M | $22M | $18M | $19M | $22M | $19M | $17M | $29M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $37M | $51M | $57M | $51M | $60M | $52M | $67M | $102M |
| Total equity | $-10M | $-29M | $-39M | $-32M | $-37M | $-32M | $-50M | $-73M |